Inotek Pharmaceuticals Reports Positive Glaucoma Study Results

Inotek has reported positive top-line results from phase 1/2 randomized, double-blind, placebo-controlled clinical trial of INO-8875, in patients with glaucoma.

The study showed that the treatment with INO-8875 was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP).

The phase 1/2 single ascending dose study, involving 84 subjects with primary open-angle glaucoma or ocular hypertension, was designed to evaluate the safety, tolerability and efficacy of INO-8875 administered topically to the eye.

Paul Howes, President and CEO of Inotek, said: We believe INO-8875 is an important investigational agent that holds great potential for the treatment of glaucoma and other indications marked by elevated IOP. We intend to continue our Phase 2 program with INO-8875 in glaucoma in 2010, while also continuing to advance our pipeline which includes novel therapeutic approaches to other serious ophthalmic diseases, including age-related macular degeneration and diabetic retinopathy.